A retrospective real-world experience of immunotherapy in patients with extensive stage small-cell lung cancer.

Guihuan QiuFei WangXiaohong XieTing LiuChen ZengZiyao ChenMaolin ZhouHaiyi DengYilin YangXinqing LinZhanhong XieGengyun SunCheng-Zhi ZhouMing Liu

Published in: Cancer medicine (2023)

ICIs combined with chemotherapy as the FL treatment could be beneficial to the ORR, DCR, PFS, and OS of ES-SCLC patients. Furthermore, ES-SCLC patients can benefit from ICIs in the second-line treatment, even if they had not received ICIs in the FL treatment.

Keyphrases

end stage renal disease
small cell lung cancer
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
squamous cell carcinoma
patient reported